Does erythropoietin have a reno-protective impact in patients undergoing Coronary Artery Bypass Grafting? A randomized, double-blind, placebo-controlled trial

Background: Open heart surgery-related acute renal insult (OHS-RARI) is a typical inconvenience following cardiovascular surgery. Erythropoietin (EPO) has been appeared from many examinations to have a renodefensive impact. Objectives: The present study was directed to explore the part of EPO in forestallingcoronary artery bypass graft surgery-related acute renal insult (CABG-RARI). Patients and Methods: Arandomized, doubleblind, placebo-controlled trial was conducted prospectively on 70 male patients admitted to the Cardiothoracic Surgery Department, Qena University Hospital, candidate for elective on-pump CABG. They were divided into two groups; group I received 200 U/kg of rHuEPO (n = 35) intravenously (IV) three days preoperative and anotherdose of 100 U/kg IV at operation time. Group II received IV isotonic saline (NaCl 0.9%) (n = 35) intravenously three days preoperative and anotherdose at operation time. The serum creatinine (SCr), estimated glomerular filtration rate (eGFR) and urine neutrophil gelatinase-associated lipocalin (NGAL) were estimated to assess OHS-RARI. Results: The overall results of the present study revealed non-significant changes in the studied biomarkers concerning with assessment of the incidence of CABG-RARI and ARI between the two groups (p˃0.05). Conclusions: Intravenous administration of 300 IU/kg of EPO did not protectagainst renaldamage in patients experiencing CABG. [Ahmed F. Abdel-latif, Salah M. Saleh, Hatem S. Mohammed, Mohamed Abdel-Bary, Mona M. Abdelmegid, Abdelkader Ahmed Hashim, Mohammed H. Hassan, Ahmed Farouk and Hany A. Ibrahim. Does erythropoietinhave a reno-protective impact in patients undergoing Coronary Artery Bypass Grafting? A randomized, double-blind, placebo-controlled trial. J Am Sci 2018;14(2):1-8]. ISSN 1545-1003 (print); ISSN 2375-7264 (online). http://www.jofamericanscience.org. 1. doi:10.7537/marsjas140218.01.